NCT07545044 2026-04-22
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
Shanghai JMT-Bio Inc.
Phase 2 Not yet recruiting
Shanghai JMT-Bio Inc.
Peking University Cancer Hospital & Institute
Fudan University
Fudan University
Tianjin Medical University Cancer Institute and Hospital
University of Kansas Medical Center
Henan Cancer Hospital
Shandong Cancer Hospital and Institute
Fudan University
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
The First Affiliated Hospital with Nanjing Medical University
ChineseAMS
National Institute of Oncology, Hungary